I hate to say it but any relevant benefit in covid ards would be discernable by now.If you take the preported benefits of the pilot study and extrapolate to 90 pts at 30 days (as per interim analysis) the results would be loud and clear and included in the announcement.
I suspect fda were privy to this prior to their decision.
Ann: Phase 3 Trial in COVID-19 ARDS Surpasses 50% Enrollment, page-231
-
- There are more pages in this discussion • 215 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.20 | $1.09 | $13.21M | 11.37M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 75212 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |